Bone Biologics Corp (BBLG) - Dilution Analysis

10-Q filing | 1.8M shares outstanding

10-Q filing | 1.8M shares outstanding

10-Q filing | 1.8M shares outstanding

8-K filing: Bone Biologics Corporation completed a public offering of common stock, pre-funded warrants, Series D warrants, and Series E warrants, resulting in net proceeds of approximately $4.3 million.

S-3 filing: Bone Biologics Corporation files an S-3 to offer and sell up to $35,000,000 of common stock and preferred stock in one or more offerings.

S-1 filing: The company is offering common stock, pre-funded warrants, Series D warrants, and Series E warrants, with H.C. Wainwright & Co., LLC acting as the exclusive placement agent.

8-K filing: Stock split 1-for-6 | Outstanding: 3,183,191 → 530,531

10-Q filing | 3.2M shares outstanding

10-K filing | 3.3M shares outstanding

10-Q filing | 2.5M shares outstanding

S-3 filing: This prospectus relates to the public offering of up to 1,617,919 shares of common stock of Bone Biologics Corporation by the selling stockholders, issuable upon the exercise of outstanding warrants.

10-Q filing | 1.8M shares outstanding

8-K filing: Bone Biologics Corporation completed an inducement transaction involving the exercise of existing warrants and the issuance of new warrants, resulting in gross proceeds of approximately $2.1 million before deducting fees and expenses. ($2.0M proceeds)

10-Q filing | 1.1M shares outstanding

8-K filing: Bone Biologics Corporation priced a public offering of 119,000 shares of common stock and warrants, as well as pre-funded warrants to purchase 662,251 shares of common stock and warrants, with the offering closing on March 6, 2024, resulting in 879,176 shares of Common Stock outstanding. ($1.5M proceeds)

S-1/A filing: The filing discusses the issuance of warrants to purchase common stock to H.C. Wainwright for placement agent services.

S-1/A filing: This S-1/A filing relates to an offering of common stock, pre-funded warrants, and warrants, with H.C. Wainwright & Co., LLC acting as the exclusive placement agent.

10-K filing | 0.5M shares outstanding

S-1 filing: This S-1 filing details a combination offering of common stock and warrants to purchase common stock, as well as pre-funded warrants for certain investors.

S-3/A filing: This prospectus relates to the public offering of up to 142,384 shares of common stock of Bone Biologics Corporation by the selling stockholders, issuable upon exercise of outstanding warrants at an exercise price of $4.16 per share and expiring on May 21, 2029.

S-3 filing: This S-3 filing relates to the public offering of up to 142,384 shares of common stock of Bone Biologics Corporation by the selling stockholders upon exercise of outstanding warrants.

8-K filing: Stock split 1-for-8 | Outstanding: 3,134,391 → 391,798

8-K filing: Bone Biologics Corporation entered into a securities purchase agreement to sell 1,139,063 shares of common stock at $0.64 per share in a registered direct offering, and agreed to issue unregistered warrants to purchase up to 1,139,063 shares of common stock, with net proceeds expected to be approximately $591,000.

10-Q filing | 3.1M shares outstanding

10-Q filing | 3.1M shares outstanding

8-K filing: Bone Biologics Corporation entered into an underwriting agreement with EF Hutton to sell 2,538,071 shares of its common stock at a public offering price of $1.97 per share.

S-1/A filing: This S-1/A filing pertains to a proposed offering of common stock and pre-funded warrants with the intention to raise capital for clinical trials, patent portfolio maintenance, CRO retention, and general corporate purposes.

S-1/A filing: This S-1/A filing outlines the offering of 1,481,481 shares of common stock at an assumed price of $5.40 per share, along with pre-funded warrants to purchase common stock, with the net proceeds intended to fund clinical trials, patent portfolio maintenance, contract research organizations, working capital, and general corporate purposes.

8-K filing: Stock split 1-for-30 | Outstanding: 16,115,577 → 537,185

10-Q filing | 16.1M shares outstanding

10-K filing | 16.7M shares outstanding

10-Q filing | 15.3M shares outstanding

8-K filing: The Company completed a public offering of 3,777,778 units, each consisting of one share of common stock and warrants, at a price of $1.35 per Unit, generating gross proceeds of $5,100,000.30. ($5.1M proceeds)

8-K filing: Bone Biologics Corporation entered into an underwriting agreement with WallachBeth Capital, LLC for a public offering of 3,777,778 units at $1.35 per unit, resulting in gross proceeds of approximately $5,100,000 before discounts and expenses, with each unit including one share of common stock and warrants. ($5.1M proceeds)

S-1/A filing: The company is offering 1,923,077 units, each consisting of one share of common stock, one Series A warrant (exercise price of $3.12), one Series B warrant (exercise price of $2.60), and one Series C warrant (exercise price of $4.16).

S-1/A filing: This S-1/A filing outlines a unit offering of common stock and warrants, intending to use the proceeds for clinical trials, patent maintenance, contract research organizations, and working capital.

S-1 filing: Bone Biologics Corporation is offering units, each consisting of one share of common stock, one Series A warrant, one Series B warrant, and one Series C warrant.

10-Q filing | 10.4M shares outstanding

S-3 filing: The filing relates to the Company's offer, sale, and issuance from time to time, pursuant to Rule 415 under the Securities Act, of the following securities of the Company with an aggregate public offering price of up to $20,000,000: (1) shares of the Company's common stock; (2) shares of the Company's preferred stock; (3) debt securities of the Company; (4) warrants to purchase shares of Common Stock, shares of Preferred Stock, or Debt Securities, or any combination of such securities; (5) stock purchase rights entitling or obligating the holders thereof to purchase Common Stock or Preferred Stock from the Company at a future date or dates and (6) units consisting of any combination of shares of Common Stock, shares of Preferred Stock, Debt Securities, and/or Warrants.

10-Q filing | 10.4M shares outstanding

10-K filing | 10.4M shares outstanding

8-K filing: Bone Biologics Corporation entered into a revised Employment Agreement with CFO Deina H. Walsh, granting her a stock option for 25,000 shares of common stock and an opportunity to invest in future financings to prevent dilution.

10-Q filing | 10.3M shares outstanding

8-K filing: The company completed a public offering of 1,510,455 units, each consisting of one share of common stock and one warrant, at a price of $5.25 per unit, generating gross proceeds of $7,929,889. ($7.93M proceeds)

8-K filing: Bone Biologics Corporation entered into an underwriting agreement for a public offering of units, each consisting of one share of common stock and one warrant, at a price of $5.25 per unit, and also effected a 1-for-2.5 reverse stock split. ($15.8M proceeds)

S-1/A filing: The company is offering units consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $9.60 per share, with the units offered at a public offering price of $8.00 per unit.

S-1/A filing: This S-1/A filing describes an offering of units, each consisting of one share of common stock and a warrant to purchase one share of common stock, with the warrants exercisable at $9.60 per share.

S-1/A filing: This is an S-1/A filing for Bone Biologics Corporation describing an offering of Units, each consisting of one share of common stock and a warrant to purchase one share of common stock.

10-Q filing | 30.7M shares outstanding

S-1 filing: This S-1 filing outlines the company's business, technology, licensing agreement with UCLA TDG, and the terms of a proposed offering of units consisting of common stock and warrants.

10-Q filing | 30.7M shares outstanding

10-Q filing | 30.7M shares outstanding

10-Q filing | 30.7M shares outstanding

10-K filing | 30.7M shares outstanding

10-Q filing | 30.7M shares outstanding

10-K filing | 30.7M shares outstanding